Clinical Trials

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT06465069 2026-03-24

NEXUS-01

Phase 1 Recruiting

420 enrolled

NCT05614739 2026-03-23

FORAGER-1

Phase 1 Recruiting

535 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT04004442 2026-03-13

COAXIN

19 enrolled

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

35 enrolled

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Phase 2 Active not recruiting

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

75 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06349668 2026-02-05

SMILe

Phase 3 Recruiting

220 enrolled

Kidney Neoplasms, Ureteral Neoplasms, Vesico-Ureteral Reflux, Nephrolithiasis

NCT02012699 2026-01-22

iCaRe2

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

999,999 enrolled

Anus Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Duodenal Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Hypopharyngeal Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Lip Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Multiple Myeloma, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Paranasal Sinus Neoplasms, Paraproteinemias, Penile Neoplasms, Peritoneal Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Central Nervous System Neoplasms, Thyroid Nodule, Endometrial Neoplasms, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

608 enrolled 22 charts 2 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT07087860 2025-12-09

RECIPE-B1

Phase 2 Recruiting

70 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT00902590 2025-09-05

A Genotype-Phenotype Urothelial Cancer Registry

Active not recruiting

3,519 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05059444 2025-08-22

ORACLE

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

2,020 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Rectal Neoplasms, Ureteral Neoplasms, Endometrial Neoplasms

NCT06983210 2025-08-14

GRAPE

Phase 2 Recruiting

43 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Phase 2 Recruiting

25 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Phase 1/2 Withdrawn

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

Phase 2 Terminated

32 enrolled 14 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03291028 2025-01-10

Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

16 enrolled

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidMyeloidNETOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT04028479 2024-12-18

ROOT

Completed

167 enrolled

Nasopharyngeal Carcinoma, Adenocarcinoma, Adrenal Gland Neoplasms, Anus Neoplasms, Appendiceal Neoplasms, Astrocytoma, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoid Tumor, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Chondrosarcoma, Colonic Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liposarcoma, Liver Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mesothelioma, Multiple Myeloma, Neoplasms, Multiple Endocrine Neoplasia, Neoplasms, Unknown Primary, Ovarian Neoplasms, Pancreatic Neoplasms, Parathyroid Neoplasms, Parotid Neoplasms, Penile Neoplasms, Pharyngeal Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Skin Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Ureteral Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Central Nervous System Neoplasms, Cholangiocarcinoma, Carcinoma, Small Cell, Neuroendocrine Tumors, Brain Stem Neoplasms, Gestational Trophoblastic Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03219333 2024-08-27

EV-201

219 enrolled 32 charts 4 FDA

GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Phase 1 Completed

175 enrolled 23 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

47 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT06469229 2024-07-05

Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria

Not yet recruiting

1,200 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Hematuria, Ureteral Neoplasms

NCT01326871 2024-06-25

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Phase 1/2 Completed

68 enrolled 13 charts

Urinary Bladder Neoplasms, Neoplasm Metastasis, Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT06427993 2024-06-20

Urine DNA Methylation Detection for Hematuria Evaluation

Not yet recruiting

71 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Hematuria, Ureteral Neoplasms

NCT03590054 2024-03-22

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Phase 1 Completed

35 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ureteral Neoplasms

NCT00942331 2023-10-16

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Phase 3 Completed

506 enrolled 13 charts

Carcinoma, Transitional Cell, Prostatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02643043 2023-09-29

UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch

Phase NA Completed

219 enrolled

EndocrineGenitourinaryGynecologic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05739812 2023-07-14

The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological Telesurgery

Phase NA Unknown

100 enrolled

Multicystic renal dysplasia, bilateral, Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Kidney Calculi, Pelvic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Ureteral Calculi, Ureteral Neoplasms

NCT03397394 2023-06-09

ATLAS

Phase 2 Terminated

97 enrolled 12 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT04625556 2023-01-31

Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome

3,000 enrolled

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Prostatic Neoplasms, Ureteral Neoplasms

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

2 enrolled 8 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Phase 2 Terminated

8 enrolled 16 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

6 enrolled

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT03179943 2021-11-04

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

21 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05043662 2021-09-14

UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.

Unknown

110 enrolled

Carcinoma, Transitional Cell, Ureteral Neoplasms

NCT00749892 2020-09-10

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

34 enrolled 9 charts

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT01846520 2020-01-23

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

Phase NA Completed

200 enrolled

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04197414 2019-12-13

Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA

3,000 enrolled

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Prostatic Neoplasms, Ureteral Neoplasms

NCT02665039 2019-10-08

VINGEM

62 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01282463 2019-09-09

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

148 enrolled 19 charts

Carcinoma, Renal Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02300610 2019-08-01

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

Phase 1 Completed

10 enrolled 14 charts